fda warning letters compounded semaglutide tirzepatide september 2025 Issues Warnings Against Illegal GLP-1 Marketing FDA Warns Telehealth Firms Over

Anti-Inflammatory Effects

Clinical data from the STEP trials showed participants using semaglutide achieved average weight loss of 10-15% of body weight over 68 weeks when combined with reduced-calorie eating and regular physical activity

The STEP and SURMOUNT trials represent some of the most rigorous weight loss medication research available, with tens of thousands of participants studied over 68-72 weeks

Finally, it is important to acknowledge the similar protective role that UA is proposed to have in Alzheimers disease, indicating an influence not restricted to the dopaminergic neurodegeneration and synucleinopathy in PD